SynthesisJournal of robotic surgery2024
Perioperative, functional, and oncological outcomes of Da Vinci vs. Hugo RAS for robot‑assisted radical prostatectomy: evidence based on controlled studies.
Synthesis in Journal of robotic surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Hugo™ RAS versus da VinciBMC surgery · 2026Pooled it
- Clinical effectiveness of enhanced recovery after surgery in robotic prostatectomy: a meta-analysis of systematic review.Journal of robotic surgery · 2025Pooled it
- Perioperative efficiency and clinical outcomes of single-port versus multi-port robot-assisted radical prostatectomy: an updated meta-analysis.Journal of robotic surgery · 2025Pooled it
- Safety and functional outcomes of Versius surgical platform in prostate cancer radical prostatectomy: a single arm meta-analysis.Journal of robotic surgery · 2025Pooled it
- Evaluating the safety, feasibility, and outcomes of the Senhance robotic system in robot-assisted radical prostatectomy: a systematic review and single-arm meta-analysis.Journal of robotic surgery · 2025Pooled it
- Exploratory activity-based direct cost analysis of robotic platforms in urologic surgery.Journal of robotic surgery · 2026Article
- Learning Curve of Docking Time in Robot-Assisted Radical Prostatectomy with the Hugo RAS System: How Many Procedures to Achieve Efficiency?Journal of clinical medicine · 2026Article
- Intraoperative outcomes of robotic surgery across multiple multimodal systems.Journal of robotic surgery · 2026Observational
- Comments on: Evaluating the safety, feasibility, and outcomes of the Senhance robotic system in robot-assisted radical prostatectomy: a systematic review and single-arm meta-analysis.Journal of robotic surgery · 2025Article
- Chemotherapeutic dihydromyricetin with remarkable anti-tumor activity and biosafety for muscle invasive bladder cancer.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A comparison was conducted between robot-assisted radical prostatectomy (RARP) performed using the Hugo RAS System and the Da Vinci System. We conducted an extensive search of online databases through September 2024. The data from eligible studies were pooled and analyzed with Review Manager 5.4, employing a random effects model. Weighted mean difference (WMD) and odds ratios (OR) with 95% confidence intervals (CI) were used to analyze continuous and categorical variables. A total of eight original studies, involving 1155 patients (HUGO-RARP: 468 vs. da Vinci-RARP: 687), were included. Compared with da Vinci-RARP, HUGO-RARP had a longer docking time (WMD: 6.2 min; 95% CI 4.25-8.14; p < 0.0001), while no significant differences were observed in total operative time, console time, bladder neck dissection time, seminal vesicle dissection time, vesicourethral anastomosis time, or pelvic lymph node dissection time between two systems. There were no significant differences in hospital stay, estimated blood loss, catheter duration, or complication rates. Likewise, oncological and functional outcomes were similar between the two systems. While these results suggest that the Hugo RAS system performs as well as the Da Vinci system in RARP, more randomized controlled studies are needed to further evaluate prognostic outcomes.
Indexed as
Identifiers
39443428What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.